Goserelin Acetate
Definition
Goserelin acetate is a synthetic (man-made) hormone that acts similarly to the naturally occurring gonadotropin-releasing hormone (GnRH). It is available in the United States under the tradename Zoladex.
Purpose
Goserelin acetate is used primarily to counter the symptoms of late-stage prostate cancer in men or is offered as an alternative to treat prostate cancer when surgery to remove the testes or estrogen therapy is not an option or is unacceptable for the patient. Goserelin is also given as combination therapy with the drug flutamide to manage prostate cancer that is locally confined and not widespread. It is often used to ease the pain and discomfort of women suffering from endometrosis and to relieve symptoms in women with advanced breast cancer.
Description
Goserelin acetate is a man-made protein that mimics many of the actions of gonadotropin-releasing hormone (GnRH). In men, this results in decreased blood levels of the male hormone testosterone. In women, it decreases blood levels of the female hormone estrogen.
Recommended dosage
Goserelin acetate is given in the form of an implant containing 3.6 mg of the medication. This implant is placed just under the skin of the upper abdominal wall. The drug lasts for 28 days, after which a new implant has to be placed. Goserelin is also available in a dose of 10.8 mg, in which case the drugs lasts for three months.
Precautions
If a woman becomes pregnant while taking this drug, goserelin acetate may cause birth defects or the loss of the pregnancy. It is not known if goserelin is passed into breast milk; therefore, it is not recommended to breast feed while on this drug.
Goserelin acetate will also interfere with the chemical actions of birth control pills. For this reason, sexually active women who do not wish to become pregnant should use some form of birth control other than birth control pills during treatment with goserelin acetate and for at least 12 weeks after the completion of treatment.
Goserelin acetate will cause sterility in men, at least for the duration of the treatment.
